The discovery of activating mutations in the ALK gene in high-risk neuroblastoma (NB) has opened new opportunities for the development of novel therapeutic strategies against this often-fatal childhood cancer of the sympathetic nervous system [1]. Here, ALK is linked to neuroblastoma.